These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
535 related items for PubMed ID: 17313628
1. Safety and efficacy of insulin detemir in clinical practice: 14-week follow-up data from type 1 and type 2 diabetes patients in the PREDICTIVE European cohort. Dornhorst A, Lüddeke HJ, Sreenan S, Koenen C, Hansen JB, Tsur A, Landstedt-Hallin L. Int J Clin Pract; 2007 Mar; 61(3):523-8. PubMed ID: 17313628 [Abstract] [Full Text] [Related]
2. Insulin detemir improves glycaemic control without weight gain in insulin-naïve patients with type 2 diabetes: subgroup analysis from the PREDICTIVE study. Dornhorst A, Lüddeke HJ, Sreenan S, Kozlovski P, Hansen JB, Looij BJ, Meneghini L, PREDICTIVE Study Group. Int J Clin Pract; 2008 Apr; 62(4):659-65. PubMed ID: 18324957 [Abstract] [Full Text] [Related]
3. Observational, open-label study of type 1 and type 2 diabetes patients switching from human insulin to insulin analogue basal-bolus regimens: insights from the PREDICTIVE study. Hermansen K, Dornhorst A, Sreenan S. Curr Med Res Opin; 2009 Nov; 25(11):2601-8. PubMed ID: 19739940 [Abstract] [Full Text] [Related]
4. Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes. Haak T, Tiengo A, Draeger E, Suntum M, Waldhäusl W. Diabetes Obes Metab; 2005 Jan; 7(1):56-64. PubMed ID: 15642076 [Abstract] [Full Text] [Related]
7. Biphasic insulin aspart 30 treatment improves glycaemic control in patients with type 2 diabetes in a clinical practice setting: Chinese PRESENT study. Gao Y, Guo XH, Vaz JA, PRESENT Study Group. Diabetes Obes Metab; 2009 Jan; 11(1):33-40. PubMed ID: 18494806 [Abstract] [Full Text] [Related]
9. Biphasic insulin aspart 30 treatment improves glycaemic control in patients with type 2 diabetes in a clinical practice setting: experience from the PRESENT study. Khutsoane D, Sharma SK, Almustafa M, Jang HC, Azar ST, Danciulescu R, Shestakova M, Ayad NM, Guler S, Bech OM, PRESENT Study Group. Diabetes Obes Metab; 2008 Mar; 10(3):212-22. PubMed ID: 18269636 [Abstract] [Full Text] [Related]
10. Insulin detemir compared with NPH insulin in children and adolescents with Type 1 diabetes. Robertson KJ, Schoenle E, Gucev Z, Mordhorst L, Gall MA, Ludvigsson J. Diabet Med; 2007 Jan; 24(1):27-34. PubMed ID: 17227321 [Abstract] [Full Text] [Related]
11. Switching patients from insulin glargine-based basal-bolus regimens to a once daily insulin detemir-based basal-bolus regimen: results from a subgroup of the PREDICTIVE study. Yenigun M, Honka M. Int J Clin Pract; 2009 Mar; 63(3):425-32. PubMed ID: 19222627 [Abstract] [Full Text] [Related]
15. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Hermansen K, Kipnes M, Luo E, Fanurik D, Khatami H, Stein P, Sitagliptin Study 035 Group. Diabetes Obes Metab; 2007 Sep; 9(5):733-45. PubMed ID: 17593236 [Abstract] [Full Text] [Related]
16. Initiating insulin therapy with, or switching existing insulin therapy to, biphasic insulin aspart 30/70 (NovoMix 30) in routine care: safety and effectiveness in patients with type 2 diabetes in the IMPROVE observational study. Valensi P, Benroubi M, Borzi V, Gumprecht J, Kawamori R, Shaban J, Shah S, Shestakova M, Wenying Y, IMPROVE Study Group Expert Panel. Int J Clin Pract; 2009 Mar; 63(3):522-31. PubMed ID: 19187170 [Abstract] [Full Text] [Related]
17. Improved glycaemic control with no weight gain: a 26-week, open label, non-randomised, non-interventional observational study on type 2 diabetes subjects using insulin detemir. Tripathi S, Chandalia HB, Rao PV, Badgandi M, Patni R, Subbanna PK, Shetty R, Kumar H. J Indian Med Assoc; 2011 Apr; 109(4):275-8. PubMed ID: 22187803 [Abstract] [Full Text] [Related]
20. Safety and efficacy of insulin detemir basal-bolus therapy in type 1 diabetes patients: 14-week data from the European cohort of the PREDICTIVE study. Dornhorst A, Lüddeke HJ, Honka M, Ackermann RW, Meriläinen M, Gallwitz B, Sreenan S, PREDICTIVE Study Group. Curr Med Res Opin; 2008 Feb; 24(2):369-76. PubMed ID: 18096110 [Abstract] [Full Text] [Related] Page: [Next] [New Search]